



PRESS RELEASE

REGULATED INFORMATION

1 February 2019, 07:00 CET

## Disclosure of a transparency notification

**Mechelen, Belgium, 1 February 2019** – Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that it received a transparency notification on 30 January 2019 (the 'Notification'), indicating that on 28 January 2019 the participation of Sycomore Asset Management SA decreased below the 5% notification threshold. It concerns a passive downward crossing.

The Notification contains the following information:

- **Reason for the Notification:** Passive crossing of a threshold.
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:** Sycomore Asset Management SA, 14 avenue Hoche, 75008 Paris, France; Sycomore Factory SAS, 14 avenue Hoche, 75008 Paris, France.
- **Transaction date:** 28 January 2019.
- **Threshold that is crossed:** 5%.
- **Denominator:** 56,361,088.
- **Details of the Notification:** Sycomore Asset Management SA holds 2,694,876 voting securities, corresponding to 4.78% of the voting rights.
- **Chain of controlled undertakings through which the holding is effectively being held:** This position is held by OPCVM, OPC and mandates managed by Sycomore Asset Management. Sycomore Asset Management is controlled by the company Sycomore Factory SAS, which does not hold voting rights for the issuer concerned and which is not a controlled entity.

For further information, reference is made to the Notification which is available [here](#) on the Biocartis website.

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

----- END -----

### More information:

Renate Degrave  
Manager Corporate Communications & Investor Relations  
e-mail [rdegrave@biocartis.com](mailto:rdegrave@biocartis.com)  
tel +32 15 631 729  
mobile +32 471 53 60 64

[@Biocartis](#) [www.linkedin.com/Biocartis](https://www.linkedin.com/Biocartis)

## **About Biocartis**

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology. This area represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: [www.biocartis.com](http://www.biocartis.com). Press Photo Library available [here](#). Follow us on [Twitter](#): @Biocartis\_.

*Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis trademark and logo and the Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.*

## **Forward-looking statements**

*This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements.*